281 related articles for article (PubMed ID: 31665867)
1. [Research progress of CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
Yang JJ; Sang W; Xu KL
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):849-852. PubMed ID: 31665867
[TBL] [Abstract][Full Text] [Related]
2. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
3. Timing of CAR-T therapy in follicular lymphoma.
Alhaj Moustafa M
Expert Rev Anticancer Ther; 2023 Apr; 23(4):347-349. PubMed ID: 36825538
[No Abstract] [Full Text] [Related]
4. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
5. CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Gideon J
Clin J Oncol Nurs; 2022 Nov; 26(6):597-601. PubMed ID: 36413724
[TBL] [Abstract][Full Text] [Related]
6. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
7. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
8. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Lin RJ; Lobaugh SM; Pennisi M; Chan HT; Batlevi Y; Ruiz JD; Elko TA; Maloy MA; Batlevi CL; Dahi PB; Giralt SA; Hamlin PA; Mead E; Noy A; Palomba ML; Santomasso BD; Sauter CS; Scordo M; Shah GL; Korc-Grodzicki B; Kim SJ; Silverberg ML; Brooklyn CA; Devlin SM; Perales MA
Haematologica; 2021 Jan; 106(1):255-258. PubMed ID: 32079691
[No Abstract] [Full Text] [Related]
9. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
Di Rocco A; Cuneo A; Di Rocco A; Merli F; De Luca G; Petrucci L; Ansuinelli M; Penna D; Rotondo F; Rigolin GM; Giaimo M; Re F; Farcomeni A; Martelli M; Foà R
Leuk Lymphoma; 2021 Apr; 62(4):828-836. PubMed ID: 33274677
[TBL] [Abstract][Full Text] [Related]
10. [Diffuse large B-cell lymphoma: a revolutionary treatment based on genetically-modified immune cells called CAR T cells].
Maquet C; Beguin Y; De Prijck B; Willems E; Servais S; Bonnet C
Rev Med Liege; 2021 May; 76(5-6):476-481. PubMed ID: 34080383
[TBL] [Abstract][Full Text] [Related]
11. [Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
Zhang Q; Xiao Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):788-792. PubMed ID: 36709176
[No Abstract] [Full Text] [Related]
12. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
13. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Caballero AC; Escribà-Garcia L; Alvarez-Fernández C; Briones J
Front Immunol; 2022; 13():904497. PubMed ID: 35874685
[TBL] [Abstract][Full Text] [Related]
14. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
Hill BT; Roberts ZJ; Xue A; Rossi JM; Smith MR
Bone Marrow Transplant; 2020 Jun; 55(6):1184-1187. PubMed ID: 31471571
[No Abstract] [Full Text] [Related]
15. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
Br J Haematol; 2023 Jan; 200(1):e4-e5. PubMed ID: 36281746
[No Abstract] [Full Text] [Related]
17. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
Chong EA; Ruella M; Schuster SJ;
N Engl J Med; 2021 Feb; 384(7):673-674. PubMed ID: 33596362
[No Abstract] [Full Text] [Related]
18. [The study of chimeric antigen receptor T (CAR-T) cell therapy in refractory/relapsed T-cell malignancies].
Li HJ; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):349-352. PubMed ID: 35680637
[No Abstract] [Full Text] [Related]
19. Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
Bajwa A; Huang Y; Li R; Denlinger N; Brammer J; Penza S; Saad A; Jaglowski S; Kittai AS
Leuk Lymphoma; 2022 Jun; 63(6):1492-1495. PubMed ID: 35109749
[No Abstract] [Full Text] [Related]
20. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Trujillo JA; Godfrey J; Hu Y; Huang J; Smith SM; Frigault MJ; DeFilipp Z; Appelbaum D; Pu Y; Feinberg N; Althaus T; Bishop MR; Riedell PA; Kline J
Blood; 2021 Jun; 137(24):3454-3459. PubMed ID: 33881502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
